MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and ...

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced that ...

QUILLIVANT ® ER Chewable Tablets have demonstrated rapid onset of action and provide consistent, continuous delivery throughout the day, 8-12 hours post-dose 6. QUILLIVANT ® ER Chewable Tablets are ...

Extended-Release Is Now Chewable: First and Only Long-Acting Chewable Methylphenidate Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 6 years old and above Monday, ...

CUPERTINO, Calif. — NextWave Pharmaceuticals, an emerging specialty pharmaceutical company, announced FDA approval of Quillivant XR((TM)) (methylphenidate hydrochloride) for extended-release oral ...

Quillivant XR is a prescription drug. It contains the active ingredient methylphenidate and is used for attention deficit hyperactivity disorder (ADHD). Quillivant XR is a liquid oral suspension ...

"The launch of QUILLIVANT® ER Oral Suspension in Canada marks a significant milestone in expanding the availability of novel, high-quality therapeutic options for physicians and patients living with ...

Quillivant XR (methylphenidate) is a brand-name drug that’s prescribed for ADHD in adults and some children. Quillivant XR comes as a powder that’s mixed with water and is typically taken once per day ...

The FINANCIAL — Pfizer on December 7 announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets. Pfizer now offers two different products for the treatment ...

CUPERTINO, Calif., Oct. 1, 2012 /PRNewswire/ -- NextWave Pharmaceuticals, an emerging specialty pharmaceutical company, announced FDA approval of Quillivant XR ™ (methylphenidate hydrochloride) for ...